Peer Review

OvaScience and Active Biotech name new CEOs, Valeant adds John Paulson to the board

Christopher Kroeger

 OvaScience struggled hard last year, dropping its CEO, COO and 30% of its staff. Now they have named a new CEO, Christopher Kroeger. Kroeger previously spent over a decade at the venture firm The Aurora Funds, and before that he ran Cardioxyl, which was sold to Bristol-Myers in 2015 for its heart failure drug. Co-founder and Chairman Michelle Dipp, who stepped in to helm the company during its turbulence, is now taking an advisory role with the fertility company.

→  Billionaire hedge funder John Paulson has been elected to the board of directors at Valeant. Chairman and CEO Joseph Papa says in a statement that “with his significant business and financial expertise, John will be a strong addition to the board. His experience will be especially valuable as we continue to execute on our transformational strategy to turnaround Valeant.” Paulson has reportedly lost nearly $2B from his stake in Valeant.

→  Helén Tuvesson is transitioning from CSO to CEO of Active Biotech AB. She is replacing CEO Tomas Leanderson, who has led the Swedish company since 2008.

→  The founder, president, CEO, and chairman of the board at Five Prime, Lewis “Rusty” Williams will be shedding a couple of those titles sometime in 2018 after the company grabs a new CEO. Williams will take on the executive chairman role and become part of the scientific advisory board once the search is complete.

→  Biogen has recruited Ginger Gregory as their new chief human resources officer, who stepped away from the exact same position at Shire. 

→  Professor Charles Swanson is the new chief clinician of Cancer Research UK. He’ll be leading the TRACERx NSCLC study.

The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription